How to Form a Research Question. Insight CF Registry Research Project

Similar documents
Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients

UK Cystic Fibrosis Registry

Cystic Fibrosis Complications ANDRES ZIRLINGER, MD STANFORD UNIVERSITY MEDICAL CENTER MARCH 3, 2012

UK Cystic Fibrosis Registry. Annual Data Report 2017

Cystic Fibrosis 8/23/2014 GROWTH DEFICIENCY IN CYSTIC FIBROSIS IS

TIMELINESS IN NEWBORN SCREENING: CONSIDERATIONS FOR CYSTIC FIBROSIS

UK Cystic Fibrosis Registry Annual Data Report

Glossary. Acronyms used in cystic fibrosis peer review reports

REGISTRY ANNUAL DATA REPORT

UK Cystic Fibrosis Registry

Canadian Cystic Fibrosis Registry

Pediatrics Grand Rounds 13 November University of Texas Health Science Center at San Antonio. Learning Objectives

Dutch Cystic Fibrosis Registy

Key Points: References: Canadian data from the Canadian Cystic Fibrosis Registry 2015 Annual Report normal

Cystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS

CYSTIC FIBROSIS REGISTRY

A contemporary survival analysis of individuals with cystic fibrosis: a cohort study

THE CANADIAN CYSTIC FIBROSIS REGISTRY

Longitudinal impact of demographic and clinical variables on Health Related Quality of Life in Cystic Fibrosis

UK Cystic Fibrosis Registry

The Future of CF Therapy

Development of novel inhaled antibiotic regimens in patients with cystic fibrosis (CF) and patients with non-cf bronchiectasis (BE)

Experience the Powder of Non-nebulized Pa Treatment

The Alan Turing Institute. Mihaela van der Schaar Ahmed Alaa

Bronchiectasis. What is bronchiectasis? What causes bronchiectasis?

HOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF

Clinical Commissioning Policy Proposition: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (Adults)

Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis 5/01/2011 CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE. D ANDERSEN.

Response to the Language Equality and Acquisition for Deaf Kids (LEAD-K) Task Force Report

At-A-Glance report 2014

THE CANADIAN CYSTIC FIBROSIS REGISTRY

At-A-Glance report 2013

CYSTIC FIBROSIS IN AUSTRALIA 2008

Cystic Fibrosis Foundation Patient Registry Annual Data Report 2006

BORN Ontario: NSO DERF Training Guide FEBRUARY 2012

You Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM

A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study,,

Key Concepts. Jie Hu, PhD., RN, FAAN

Relationships and Sexuality Education. Information for Parents

PERINATAL HEPATITIS B

Preface of the special issue: Recent CMV Research

Dutch Cystic Fibrosis Registry

Novel Therapies for NTM

UK Cystic Fibrosis Registry

Patient Group Input to CADTH

Characterizing aggressiveness and predicting future progression of CF lung disease

Pulmonary Exacerbations:

Pulmonary Medicine. Shaping the Future of Cystic Fibrosis Care

From CF Adult and Family Advisors (AFA) to Community Voice

Icd 10 for asymptomatic bacteriuria

How Registries can be used to improve trans-national care

What Women Need to Know: The HIV Treatment Guidelines for Pregnant Women

A regulatory perspective What do I want to know?

Dutch Cystic Fibrosis Registry

Cystic Fibrosis. Advances and Asian Perspective Dr AS Paul 13 October 06

Cystic Fibrosis Registry of Ireland 2012 Annual Report

Cystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL

Clinical and Microbiological Impact of Inhaled Tobramycin Treatment on Cystic Fibrosis Patients with Pseudomonas aeruginosa

Program Begins Below. No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Swiss Summary of the Risk Management Plan (RMP) for Nucala (Mepolizumab)

NI Health & Social Care Inequalities Monitoring System Sub-regional Inequalities - HSC Trusts 2010

Caregiver burden and quality of life of parents of young children with cystic fibrosis

The David Conforti Reach for the Stars Award

Disease-Atlas: Navigating Disease Trajectories with Deep Learning. Bryan Lim & Mihaela van der Schaar University of Oxford

PTSD for PAG Clinicians: Empowering Young Women with PTSD

Chapter 3 The Role of Nutrition in CF Care

Recommendations for Hospital Quality Measures in 2011:

UK Cystic Fibrosis Registry 2014 Annual Data Report

Communicating About Ebola: A Guide for Leaders. Produced by the Pan American Health Organization

SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018

ANNUAL REPORT 2015 AUSTRALIAN CYSTIC FIBROSIS DATA REGISTRY. This publication was produced with the support of Cystic Fibrosis Australia.

THE BELGIAN CYSTIC FIBROSIS REGISTRY

BMR Be l g i s c h Mu c o v i s c i d o s e Re g i s t e r

Factors associated with changes in health-related quality of life in children with cystic fibrosis during 1-year follow-up

4.0 Product Testing. 4.1 Routine Testing

Focus on Cystic Fibrosis. Cystic Fibrosis. Cystic Fibrosis

About Your Ventricular Assist Device (VAD) Surgery

Patient and public involvement. Guidance for researchers

Patient Registry. Annual Data Report

ESPEN Congress Nice From child to adult nutrition. Cystic fibrosis. A. Munck

Making Connections: Early Detection Hearing and Intervention through the Medical Home Model Podcast Series

CF, Mental Health, TAYLOR GONZALEZ. & Exercise

Pseudomonas aeruginosa eradication guideline

Q1 Do you identify as?

Changes in the management of children with Cystic Fibrosis. Caroline Murphy & Deirdre O Donovan CF Nurses

CRN Wessex Patient Research Experience Survey 2017/18 Report

Childhood Undernutrition: a biological perspective

The ecology of disease interactions in CF

Lung Transplant for Cystic Fibrosis

The Process of Measurement: An Overview

Pediatrics Skills Checklist

Comparison of growth status of patients with cystic fibrosis between the United States and Canada 1 3

Summary of the risk management plan (RMP) for Duloxetine Lilly (duloxetine)

Respiratory infection rates differ between geographically distant paediatric cystic fibrosis cohorts

Priorities for achieving Millennium Development Goals (MDGs) 4 and 5 in the European Region

Bilateral Wilms Tumor: New Protocols and Procedures by Dawn Wolf

PORT CFNZ National Data Registry ~ 1 ~

AUSTRALIAN CYSTIC FIBROSIS DATA REGISTRY ANNUAL REPORT This publication was produced with the support of Cystic Fibrosis Australia.

Most candidates were able to gain marks on this question, though there were relatively few who were able to explain interpretive sociology.

Transcription:

How to Form a Research Question Insight CF Registry Research Project

Insight CF Registry Research Project Thank you for your interest in the Insight CF Registry Research Project. The goal of this training is to help you develop a research question to submit for the project through the form at www.cff.org/insightcf. This training covers: The process of scientific research How to come up with ideas for research How to turn an idea into a research question The four elements of a research question: What? How? Who? Why?

How Does the Research Process Work? Form a Research Question Specifies the knowledge to be gained from the research study Addresses information missing from previous research Disseminate Results Shares the study findings, acknowledging the study s strengths and limitations Findings may lead to further questions continuing the cycle Design the Study Outlines the protocol and procedures for the study Describes the analytic techniques to allow valid interpretations of the results Implement the Study Collect data Conduct data analysis Ultimately, Insight CF will include all phases of research. We are starting with research questions.

Formulating a Research Question Why? What? How? Who?

How Do I Come Up With a Research Idea? Research ideas are all around us. They are the things you wonder as you live your life with CF: Consider times when you needed to make a decision and wanted more information to help you make that decision. Consider information you heard or read and wondered if it was accurate. Consider differences between people you know with CF and wondered why their CF was different. Would moving to a different climate affect my health? I wonder Should I consider adding a medication? Does my mental health affect my physical health?

Turning Your Idea Into a Research Question Not all ideas or questions are research questions. Research questions: Involve the comparison of two groups of people Have an answer that is a measure of the magnitude of the difference between the two groups of people Here is an example of the difference between a regular question and a research question: How many people with CF have CF-related diabetes (CFRD)? Do individuals with CFRD have worse lung function than those without CFRD?

A Research Question Has Four Elements 1. 2. 1. 2. WHAT are the groups of people that will be compared? HOW would I measure differences between these groups? 3. 4. 3. 4. WHO will be included in the study? WHY is this important?

What? The first thing we must establish for our research question is what are the groups of people that will be compared? Most any group of people can be compared with another group. It is important that these two groups of people are different in at least one obvious way Examples of groups to compare: Males and females Individuals diagnosed with CF in the first year of life compared to individuals diagnosed after their first birthday Infants with meconium ileus at birth compared to infants without meconium ileus Children who are underweight for their age compared to children with average weight for their age Adults aged 18 24 in college compared to those not in college Individuals who cultured positive for nontuberculous mycobacteria compare to those with a negative culture Individuals taking an antibiotic compared to those not taking that antibiotic 1.

How? The second component is how to measure the difference you suggest we measure. This tells us how we know if there is a difference between the two groups of people. Examples could include comparing two groups to examine differences in the: Average FEV 1 % predicted Average number of centimeters that children grew Percentage of individuals who develop a new infection with Burkholderia cepacia Percentage of individuals who received a feeding tube Percentage of individuals who screen positive for anxiety Percentage of individuals who survived Percentage of women who report pregnancies 2.

Who? Depending on the study, it may not make sense to include the entire Registry population. Once you have selected your two distinct groups, you may consider narrowing who belongs in those groups based on the following factors. You may narrow the population in your groups based on: Time: You may want to examine an effect in the recent past, or you may want to examine populations before or after an event in the history of CF care. For example, research could study groups before or after there was universal newborn screening or before orafter a CF medication became available. Age: Some studies may relate only to infants, adolescents or adults. For studies that examine lung function, research must start with children age 6, because lung function measurements are not recorded beforehand. Sex: You may want to include only males or females for biological, psychological or sociological reasons. 3. Individuals who already have the outcome: For example, if your study is measuring the number of people who need transplants then you would need to exclude individuals who already had a transplant from the study.

Why? On the question submission form, you are asked, Why is this study important to you, and why do you think it is important for the wider CF community? This is your opportunity to build your case for the importance of your questions to the CF community. Points to consider: What are the implications to the CF community of not having this question answered? How many people in the CF community would benefit from an answer? 4. What is the potential impact of knowing the answer to your research question?

Example Research Questions Among individuals with an FEV 1 % predicted less than 40%, do those referred for transplant differ from those not referred with regard to HOW? type of health insurance and distance from their home to a transplant center? HOW? Does the percentage of individuals with Pseudomonas aeruginosa infections differ between children aged 6 to 18 living in the northeastern, southern, midwestern and western regions of the U.S.? Ramos, K.J. et al. J Cyst Fibros 15 (2016):196-203 Kopp, B.T et al. J Pediatr 2016 170:246-52

Thank you! We appreciate your time and interest in the Insight CF Registry Research Project, and look forward to receiving your research questions. To see how the submitted questions will be reviewed and learn about the next steps, please go to www.cff.org/insightcf. For questions and feedback, please contact: insightcf@cff.org.